Apatinib, namely Apatinib mesylate tablets, has certain efficacy in the treatment of gastric adenocarcinoma and other diseases, but there are individual differences in efficacy, and it is necessary to follow the doctor’s instructions to use the drug.
Apatinib mesylate is a tyrosine kinase inhibitor, which can inhibit tumor angiogenesis. Tumors with abundant blood vessels on the lesion are more suitable for the treatment of this product. This product is used for advanced gastric adenocarcinoma and gastro-esophageal adenocarcinoma that has recurred or progressed after receiving systemic chemotherapy.
Clinical application shows that the application of Apatinib Mesylate Tablets can achieve the efficacy of tumor shrinkage, but the efficacy of the treatment varies according to the different tumor conditions, sensitivity to drugs and individual tolerance and other factors.
This product may have adverse reactions such as elevated blood pressure, hand-foot syndrome, bleeding, cardiotoxicity, hepatotoxicity.
The drug is contraindicated in people who are allergic to the product, for people with active bleeding or ulcers, intestinal obstruction, intestinal perforation, and severe hepatic or renal insufficiency.
The drug should be used rationally under the guidance of a doctor.